Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Liposomal Daunorubicin Receives Orphan Medicinal Product Designation in European Union for the Treatment of Acute Myeloid Leukaemia

CRAIGAVON, Northern Ireland, November 15, 2012 /PRNewswire/ --

Galen announced today that the European Commission has designated liposomal daunorubicin as an orphan medicinal product for the treatment of acute myeloid leukaemia (AML).[1]  The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA).[2]  Liposomal daunorubicin is currently approved in a number of European countries, the U.S. and Brazil for the treatment of advanced HIV-related Kaposi's sarcoma, as the medicinal product DaunoXome®.

Acute myeloid leukaemia is estimated to affect not more than 1.2 in 10,000 people in the European Union.  It is chronically debilitating and life threatening due to bone marrow dysfunction. If left untreated, the condition progresses rapidly and is often fatal.[2]

Galen is dedicated to supporting the development and provision of innovative medicines in an effort to improve health worldwide.  Speaking about the European Commission orphan medicinal product designation for liposomal daunorubicin, Mark Scrutton, President of Galen, commented: "We are delighted about the designation of liposomal daunorubicin as an orphan medicinal product for the treatment of acute myeloid leukaemia, a life-threatening disease. We have recently taken our first step into the oncology arena, and the orphan designation of liposomal daunorubicin provides further opportunity for development of this product in the treatment of patients with AML."  

Notes to Editor:

About liposomal daunorubicin: Liposomal daunorubicinis an anthracycline chemotherapy agent which is currently approved in a number of European countries, the U.S. and Brazil for the treatment of advanced HIV-related Kaposi's sarcoma, as the medicinal product DaunoXome®. It works by attacking cancer cells and interfering with DNA production, which stops cancer cells from multiplying.[3] The product has a different delivery system compared with conventional anthracyclines; it has a type of liposomal coating and particle size, which enables it to effectively target malignant tumours.[4],[5],[6]

About Galen:

Galen is a privately owned, global pharmaceutical company headquartered in Northern Ireland, UK.  Galen's products are now available in 16 countries and the company is working to expand its global reach with the formation of international strategic partnerships.  A substantial drug discovery operation is underway, focusing on products for the treatment of cancer.  

References

  1. Community Register of Orphan Medicinal Products for Human Use, EU Designation: EU/3/12/1056. Available from http://ec.europa.eu/health/documents/community-register/html/orphreg.htm (accessed on 01 November 2012).
  2. Committee for Orphan Medicinal Products (COMP) Minutes of the 4-5 September 2012 Meeting, EMA/COMP/471400/2012, 05 October 2012.
  3. Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition.  New York, Chicago, San Francisco, McGraw-Hill.  2011: 1671.
  4. DaunoXome® Injection (liposomal daunorubicin) UK Summary of Product Characteristics 30 October 2011.
  5. Forssen EA et al.  Fluorescence Imaging Studies for the Disposition of Daunorubicin Liposomes (DaunoXome) within Tumor Tissue. Cancer Res 1996;56:2066-2075.
  6. Forssen EA.  The design and development of DaunoXome for solid tumor targeting in vivo.  Advanced Drug Delivery Reviews 1997; 24: 133-150.

 


About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
Many people recognize DevOps as an enormous benefit – faster application deployment, automated toolchains, support of more granular updates, better cooperation across groups. However, less appreciated is the journey enterprise IT groups need to make to achieve this outcome. The plain f...
AlertSite is now integrated with Ready! API. This means that developers, testers and operations teams can collaborate together on API quality using the same tests and metrics, simplifying configuration of monitoring assets and ultimately turning around performance problems in real tim...
With careful planning and the right technology, Federal, State and Local Government IT Leaders can overcome fears of data migrations, breaking free from archaic procedures to lead the pack . Jurassic World, the latest installment in the Jurassic Park film series, opened this week - an...
Can wearable technology help to prolong your life? We already know more conventional forms of tech, can save lives in a definitive manner, as well as keep people in comas and other unconscious states alive for an indeterminate period of time, but how can smaller, wearable gadgets help ...
I just read a new booklet from O’Reilly called The Software Paradox by Stephen O’Grady. You can access it here. Here is a direct quote: “This is the Software Paradox: the most powerful disruptor we have ever seen and the creator of multibillion-dollar net new markets is being commerc...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE